Revolution Medicines recently made history with the approval of its RAS inhibitor Rasonque for advanced pancreatic cancer. But behind RevMed is an entire field of biotechs working to broaden the reach of RAS-targeting drugs.

In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia sits down with Verastem Oncology CEO Dan Paterson and Chief Scientific Officer Jonathan Pachter, Ph.D., to discuss the significance of Revolution Medicines’ recent pancreatic cancer approval, Verastem’s work in the RAS-targeting space and how the company is trying to improve on existing approaches.

To learn more about the topics in this episode:

FDA greenlights Revolution Medicines' pancreatic cancer gamechanger

As RevMed preps for ‘historic’ pancreatic cancer launch, questions linger on the ground

ASCO: Revolution Medicines confident in RAS leadership as rivals square up

See omnystudio.com/listener for privacy information.

The future of RAS inhibitors

The Top Line

The future of RAS inhibitors